PL369535A1 - Zastosowanie antagonistów receptora NK-1 w leczeniu uszkodzenia mózgu, rdzenia kręgowego lub nerwów - Google Patents

Zastosowanie antagonistów receptora NK-1 w leczeniu uszkodzenia mózgu, rdzenia kręgowego lub nerwów

Info

Publication number
PL369535A1
PL369535A1 PL02369535A PL36953502A PL369535A1 PL 369535 A1 PL369535 A1 PL 369535A1 PL 02369535 A PL02369535 A PL 02369535A PL 36953502 A PL36953502 A PL 36953502A PL 369535 A1 PL369535 A1 PL 369535A1
Authority
PL
Poland
Prior art keywords
spinal
brain
treatment
receptor antagonists
nerve injury
Prior art date
Application number
PL02369535A
Other languages
English (en)
Other versions
PL211246B1 (pl
Inventor
Torsten Hoffmann
Alan John Nimmo
Andrew Sleight
Pierre Vankan
Robert Vink
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL369535A1 publication Critical patent/PL369535A1/pl
Publication of PL211246B1 publication Critical patent/PL211246B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
PL369535A 2001-07-10 2002-07-03 Zastosowanie antagonistów receptora NK-1 do wytwarzania leku do leczenia i/lub profilaktyki uszkodzenia mózgu, rdzenia kręgowego lub nerwów PL211246B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01116812 2001-07-10

Publications (2)

Publication Number Publication Date
PL369535A1 true PL369535A1 (pl) 2005-05-02
PL211246B1 PL211246B1 (pl) 2012-04-30

Family

ID=8178001

Family Applications (1)

Application Number Title Priority Date Filing Date
PL369535A PL211246B1 (pl) 2001-07-10 2002-07-03 Zastosowanie antagonistów receptora NK-1 do wytwarzania leku do leczenia i/lub profilaktyki uszkodzenia mózgu, rdzenia kręgowego lub nerwów

Country Status (23)

Country Link
US (3) US20030083345A1 (pl)
EP (2) EP1406618A2 (pl)
JP (1) JP2004536119A (pl)
KR (1) KR100589106B1 (pl)
CN (1) CN100346789C (pl)
AR (1) AR037008A1 (pl)
AU (1) AU2002328837B2 (pl)
BR (1) BR0210893A (pl)
CA (1) CA2451566C (pl)
GT (1) GT200200143A (pl)
HR (1) HRP20031071A2 (pl)
HU (1) HUP0401210A3 (pl)
IL (1) IL159350A0 (pl)
MX (1) MXPA04000278A (pl)
NO (1) NO332847B1 (pl)
NZ (1) NZ530107A (pl)
PA (1) PA8549901A1 (pl)
PE (1) PE20030238A1 (pl)
PL (1) PL211246B1 (pl)
RU (1) RU2304435C2 (pl)
UY (1) UY27374A1 (pl)
WO (1) WO2003006016A2 (pl)
ZA (1) ZA200400138B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000366A (es) * 2000-07-14 2003-05-27 Hoffmann La Roche N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.
RU2347777C2 (ru) * 2003-07-03 2009-02-27 Ф.Хоффманн-Ля Рош Аг Двойные агонисты nk1/nk3 для лечения шизофрении
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
MX2007010034A (es) * 2005-02-22 2007-10-04 Hoffmann La Roche Antagonista de nk1.
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
ATE425144T1 (de) * 2005-03-23 2009-03-15 Hoffmann La Roche Metaboliten für nk-i-antagonisten zur emesis
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
DE102007018151A1 (de) * 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP2010533655A (ja) * 2007-07-19 2010-10-28 アデレイド リサーチ アンド イノベーション ピーティーワイ リミテッド 頭蓋内圧を低下させるための方法
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
EP2639224B1 (en) 2007-12-07 2016-08-24 Vertex Pharmaceuticals Incorporated Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
RU2016103099A (ru) * 2013-07-02 2017-08-07 Юстрэлиз Фармасьютикалз Лимитед (Трейдинг Эз Пресшура Нейро) Способ предотвращения и/или лечения хронической травматической энцефалопатии - i
AU2014286926A1 (en) * 2013-07-02 2015-12-17 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-II
EP3016658A4 (en) * 2013-07-02 2017-03-15 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-iv
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
PT3221692T (pt) 2014-11-18 2021-09-10 Vertex Pharma Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
MX2020008138A (es) * 2018-02-02 2020-10-19 Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro Formulaciones parentales y usos de estas.
KR101970099B1 (ko) * 2018-02-07 2019-04-17 한국과학기술연구원 척수 손상의 예방 및 치료용 조성물
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
WO2021035289A1 (en) 2019-08-23 2021-03-04 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Therapeutic methods and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5607947A (en) * 1995-02-21 1997-03-04 Eli Lilly And Company Pyrrolidinyl tachykinin receptor antagonists
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
TW382017B (en) * 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
CA2291734A1 (en) * 1997-06-27 1999-01-07 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
KR100437587B1 (ko) * 1999-02-24 2004-06-30 에프. 호프만-라 로슈 아게 3-페닐피리딘 유도체 및 그의 뉴로키닌-1 수용체길항제로서의 용도
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment

Also Published As

Publication number Publication date
AR037008A1 (es) 2004-10-20
RU2304435C2 (ru) 2007-08-20
US20110053954A1 (en) 2011-03-03
PE20030238A1 (es) 2003-03-19
NO332847B1 (no) 2013-01-21
WO2003006016A2 (en) 2003-01-23
UY27374A1 (es) 2003-03-31
EP1621195A3 (en) 2010-01-06
KR100589106B1 (ko) 2006-06-14
WO2003006016A3 (en) 2003-07-31
GT200200143A (es) 2002-11-11
AU2002328837B2 (en) 2005-05-05
CA2451566A1 (en) 2003-01-23
ZA200400138B (en) 2005-06-29
HRP20031071A2 (en) 2004-06-30
BR0210893A (pt) 2004-06-22
US20060247240A1 (en) 2006-11-02
RU2004102397A (ru) 2005-04-20
NZ530107A (en) 2006-01-27
US20030083345A1 (en) 2003-05-01
CN100346789C (zh) 2007-11-07
IL159350A0 (en) 2004-06-01
JP2004536119A (ja) 2004-12-02
EP1621195A2 (en) 2006-02-01
PL211246B1 (pl) 2012-04-30
HK1068266A1 (en) 2005-04-29
PA8549901A1 (es) 2003-01-24
CA2451566C (en) 2013-09-10
KR20040029362A (ko) 2004-04-06
MXPA04000278A (es) 2004-05-04
NO20040057L (no) 2004-01-07
HUP0401210A3 (en) 2011-07-28
HUP0401210A2 (hu) 2004-10-28
EP1406618A2 (en) 2004-04-14
CN1523988A (zh) 2004-08-25

Similar Documents

Publication Publication Date Title
HRP20031071A2 (en) Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury
IL150548A0 (en) Brain, spinal and nerve injury treatment
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
EP1420854A4 (en) TREATMENT OF NEUROPSYCHIATRIC DISORDERS BY NERVE STIMULATION NEAR THE DIAPHRAGM
PL373626A1 (pl) Leczenie zaburzeń centralnego układu nerwowego
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
IL157815A0 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
PT2266594E (pt) Vegf para utilização no tratamento de distúrbios do sistema nervoso central
IL176581A0 (en) Immunomodulatory compounds for the treatment of central nervous system disorders
IL160483A0 (en) Treatment of disorders by unidirectional nerve stimulation
SI1474416T1 (sl) Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj
GB0428462D0 (en) Spinal cord stimulation as treatment for functional bowel disorders
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
ZA200402514B (en) 4[Piperidin-4-yliden-(3-carbamoylphenyl)methyl]benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders.
PL368556A1 (pl) Sposoby leczenia albo zapobiegania chorobom skóryprzy zastosowaniu czynników wiążących CD2
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
PL366640A1 (pl) Pochodne 4-(fenylopiperydyn-4-ylidenometylo) benzamidu i ich zastosowanie w leczeniu bólu, lęku lubzaburzeń żołądkowo-jelitowych
IL162475A0 (en) Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
IL158703A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158632A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158695A0 (en) 4-(phenyl-piperidin-4-yldine-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL162053A0 (en) Method for the treatment of bone disorders
AU2003264297A1 (en) Use of vanilloid receptor antagonists for the treatment of pain
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia

Legal Events

Date Code Title Description
RECP Rectifications of patent specification